Sam Sinai, PhD, is a co-founder and head of Computation at Dyno Therapeutics, a gene therapy company founded in 2018 and based in Watertown, MA. Dyno is a pioneer in solving some of the most challenging problems in gene therapy using artificial intelligence, which could help millions of people with untreatable genetic or acquired illnesses. Sam developed the underpinnings of the AI algorithms that Dyno uses to design therapeutic viruses, which were published in leading journals Science and Nature Biotechnology as well as leading AI conferences. Since its founding, Dyno has won Xconomy startup of the year in 2020, Endpoints promising startup in 2021,  NEVY Emerging company of the year in 2022, as well as making into Forbes' list of best startup employers in 2022.  In 2021, Dyno raised a $100 million series A round and currently employs more than 100 people across North America. Dyno has so far reached partnership deals worth up to billions of dollars, with global brands such as Novartis and Roche, among others. Before Dyno, Sam received his PhD in Biology from Harvard in 2019, supervised by scientists Martin Nowak and George Church. Sam received a B.Sc. and M.Eng. from MIT in computer science and AI. He is a co-author on more than 20 scientific publications and holds co-inventorship in several patent applications. He has also written publicly on issues concerning science, medicine, immigration in general publications such as Slate, Forbes, and Quartz.